NYSE:MRKPharmaceuticals
Merck’s Calderasib Plus Keytruda Wins FDA Boost In KRAS NSCLC Potential
Merck (NYSE:MRK) received FDA Breakthrough Therapy designation for calderasib (MK-1084) in combination with KEYTRUDA.
The designation covers first-line treatment of advanced or metastatic NSCLC with KRAS G12C mutation and PD-L1 expression.
This is the first Breakthrough Therapy designation for calderasib, aimed at expediting development and regulatory review.
For investors tracking NYSE:MRK, this update is closely tied to the company’s oncology franchise, centered on KEYTRUDA and related...